Some studies reveal that serotonin 2A receptor activation may not be necessary for the potential therapeutic effects of psychedelics.
MDMA supplements treatment of co-occurring trauma and eating disorders
Researchers suggest that the benefits of psychedelic treatment are mediated by a reduction in death anxiety and existential distress.
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
This innovation may pave the way for pharmaceuticals that act like psychedelics at the 5-HT2A receptor but don’t have hallucinogenic effects.
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
A recent study indicates that the empathogenic effects of LSD may be independent of serotonin 2A receptor activation.
A fresh theoretical framework for understanding the role of awe in Psychedelic Assisted Psychotherapy.
The truth is that scientists don’t know enough about them. And research into any athletic-enhancing capabilities they may have is lacking.